Company Description
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform.
The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer.
The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program.
Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.
| Country | United States |
| Founded | 2018 |
| IPO Date | Nov 15, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 78 |
| CEO | Peter Blume-Jensen |
Contact Details
Address: 480 Arsenal Way, Suite 100 Watertown, Massachusetts 02472 United States | |
| Phone | 617 207 8979 |
| Website | acrivon.com |
Stock Details
| Ticker Symbol | ACRV |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $12.50 |
| CIK Code | 0001781174 |
| CUSIP Number | 004890109 |
| ISIN Number | US0048901096 |
| Employer ID | 82-5125532 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Peter Blume-Jensen M.D., Ph.D. | Co-Founder, Chairman of the Board, Chief Executive Officer, President and Acting Chief Scientific Officer |
| Kristina Masson M.B.A., Ph.D. | Co-Founder, Executive Vice President of Business Operations, Site Head, Treasurer and Director |
| Dr. Eric J. Devroe Ph.D. | Chief Operating Officer |
| Dr. Adam D. Levy M.B.A., Ph.D. | Chief Financial Officer and Principal Financial Officer |
| Katharine Peterson CPA | Vice President of Finance and Accounting |
| Mary-Alice Miller J.D. | Chief Legal Officer and Corporate Secretary |
| Dr. Erick Gamelin M.D., Ph.D. | Chief Development Officer |
| Dr. Jesper V. Olsen Ph.D. | Academic Co-Founder, Head of Phosphoproteomics and Member of Scientific Advisory Board |
| Joon Jung Ph.D. | Vice President and Head of Data Science |
| Dr. Thomas P. Nifong M.D. | Head of Clinical CDx Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 13, 2025 | 8-K | Current Report |
| Jun 4, 2025 | SCHEDULE 13G/A | Filing |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 14, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 14, 2025 | 10-Q | Quarterly Report |
| May 14, 2025 | 8-K | Current Report |
| May 1, 2025 | SCHEDULE 13G/A | Filing |
| Apr 25, 2025 | ARS | Filing |
| Apr 25, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2025 | DEF 14A | Other definitive proxy statements |